Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
3 raisons identifiées
Plateau technique de référence
Assistance publique – Hôpitaux de Paris (APHP) — équipements et expertise pointus pour les cas complexes
Auteur de référence en rhumatologie
36 articles scientifiques publiés — un praticien à la pointe de la recherche
Délais de RDV courts dans la région
336.2 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.
Influence scientifique
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
20
20 articles ont été cités au moins 20fois par d'autres chercheurs — preuve que ses travaux sont repris par la communauté médicale.
h-index
Total citations reçues
1 605
Nombre de fois où d'autres équipes ont mentionné ses publications dans leurs propres travaux.
Publications totales
78
Articles, revues et chapitres référencés dans les bases académiques internationales.
Articles influents
28
Publications ayant marqué leur domaine — chacune citée au moins 10 fois par d'autres chercheurs.
i10-index
Thématiques principales
Affiliations FR : Université Paris Cité · Sorbonne Paris Cité · Hôpital Cochin
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Sweat chloride and lung function responses to elexacaftor–tezacaftor–ivacaftor in people with cystic fibrosis with two versus one responsive CFTR variants: an analysis of two real-world observational studies
2025ArticleThe Lancet Respiratory Medicine
Identification of structural predictors of lung function improvement in adults with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor using deep-learning
2025ArticleDiagnostic and Interventional Imaging
The expanded French compassionate programme for elexacaftor–tezacaftor–ivacaftor use in people with cystic fibrosis without a F508del CFTR variant: a real-world study
2024ArticleThe Lancet Respiratory Medicine
Multisystemic Effects of Elexacaftor–Tezacaftor–Ivacaftor in Adults with Cystic Fibrosis and Advanced Lung Disease
2024ArticleAnnals of the American Thoracic Society
Reversal of cylindrical bronchial dilatations in a subset of adults with cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftor
2024ArticleEuropean Respiratory Journal
Diagnosis Yield and Safety of Surgical Biopsy in Interstitial Lung Diseases: A Prospective Study
2022ArticleAnnals of Thoracic Surgery
Otological Manifestations in Adults with Primary Ciliary Dyskinesia: A Controlled Radio-Clinical Study
2022ArticleJournal of Clinical Medicine
TTC12 loss-of-function mutations cause primary ciliary dyskinesia and unveil distinct dynein assembly mechanisms in motile cilia versus flagella
2022CongrèsAssises de Génétique
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
GHU APHP CUP SITE COCHIN PORT ROYAL
27 R DU FAUBOURG SAINT JACQUES, 75679 PARIS CEDEX 14
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Antimicrobial agents and chemotherapy · 2012
ABSTRACT Aspergillus fumigatus is the most frequent fungus found in the sputum of cystic fibrosis (CF) subjects. Itraconazole is prescribed for allergic bronchopulmonary aspergillosis (ABPA) or Aspergillus bronchitis in CF subjects. We hypothesized that A. fumigatus isolates in the sputum of CF subjects with previous exposure to itraconazole was associated with higher prevalence of azole resistance. From June 2010 to April 2011, sputum samples from adult CF subjects at Cochin University Hospital (France) were examined systematically for the detection of A. fumigatus . MICs of A. fumigatus isolates against azoles were screened using Etest, and reduced susceptibility to azoles was confirmed using the CLSI broth microdilution method. A. fumigatus was isolated from the sputum of 131/249 (52.6%) adult CF subjects, and 47/131 (35.9%) subjects had received previous treatment with itraconazole. Reduced A. fumigatus susceptibility to itraconazole (MIC, ≥2 mg/liter) was confirmed in 6/131 (4.6%) subjects. All 6 isolates also had reduced susceptibility to posaconazole (MIC, ≥0.5 mg/liter), and 3/6 isolates had reduced susceptibility to voriconazole (MIC, ≥2 mg/liter). Mutations in the cyp51A gene were detected at positions previously implicated to cause resistance in 5 isolates. Azole-resistant A. fumigatus isolates were found in 5/25 (20%) subjects exposed to itraconazole within the previous 3 years. High rates of azole-resistant A. fumigatus isolates were present in adult CF subjects and were associated with recent itraconazole exposure. Although the clinical implications of these findings will require further studies, the cautious use of itraconazole in adult CF subjects can be recommended.
The European respiratory journal · 2017
The European respiratory journal · 2023
BackgroundThe European Medicines Agency has approved the cystic fibrosis transmembrane conductance regulator (CFTR) modulator combination elexacaftor-tezacaftor-ivacaftor (ETI) for people with cystic fibrosis (pwCF) carrying at least one F508del variant. The United States Food and Drug Administration (FDA) also approved ETI for pwCF carrying one of 177 rare variants.MethodsAn observational study was conducted to evaluate the effectiveness of ETI in pwCF with advanced lung disease that were not eligible to ETI in Europe. All patients with no F508del variant and advanced lung disease (defined as having a percent predicted forced expiratory volume (ppFEV1)<40 and/or being under evaluation for lung transplantation) and enrolled in the French Compassionate Program initiated ETI at recommended doses. Effectiveness was evaluated by a centralized adjudication committee at 4–6 weeks in terms of clinical manifestations, sweat chloride concentration and ppFEV1.ResultsAmong the first 84 pwCF included in the program, ETI was effective in 45 (54%) and 39 (46%) were considered to be non-responders. Among the responders 22/45 (49%) carried aCFTRvariant that is not currently approved by FDA for ETI eligibility. Important clinical benefits, including suspending the indication for lung transplantation, a significant decrease in sweat chloride concentration by a median [IQR] −30 [-14;-43]mmol·l−1(n=42;p<0.0001) and an improvement in ppFEV1by+10.0 [6.0; 20.5] (n=44,p<0.0001), were observed in those for whom treatment was effective.ConclusionClinical benefits were observed in a large subset of pwCF with advanced lung disease andCFTRvariants not currently approved for ETI.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Diagnostic and interventional imaging · 2026 · Journal Article
Chassagnon G, Marini R, Ong V, Da Silva J, et al.
Journal of clinical & translational endocrinology · 2025 · Journal Article
Burnet E, Grunewald D, Larger E, Camus-Bablon F, et al.
The European respiratory journal · 2024 · Journal Article
Cazier P, Chassagnon G, Dhote T, Da Silva J, et al.
Revue des maladies respiratoires · 2023 · Observational Study
Akdime F, Habib S, Regard L, Terrier B, et al.
The European respiratory journal · 2023 · Journal Article
Burgel PR, Sermet-Gaudelus I, Durieu I, Kanaan R, et al.
The European respiratory journal · 2023 · Letter
Dhote T, Martin C, Regard L, Pesenti L, et al.
JAMA dermatology · 2023 · Journal Article
Okroglic L, Sohier P, Martin C, Lheure C, et al.
Journal of clinical medicine · 2022 · Journal Article
Alexandru M, de Boissieu P, Benoudiba F, Moustarhfir M, et al.
The European respiratory journal · 2021 · Journal Article
Shoemark A, Rubbo B, Legendre M, Fassad MR, et al.
ERJ open research · 2020 · Journal Article
Goutaki M, Papon JF, Boon M, Casaulta C, et al.
American journal of human genetics · 2020 · Journal Article
Thomas L, Bouhouche K, Whitfield M, Thouvenin G, et al.
Journal of clinical medicine · 2019 · Journal Article
Bequignon E, Dupuy L, Zerah-Lancner F, Bassinet L, et al.
BMC pulmonary medicine · 2018 · Journal Article
Hoang-Thi TN, Revel MP, Burgel PR, Bassinet L, et al.
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2018 · Journal Article
Burnet E, Hubert D, Champreux J, Honoré I, et al.
The European respiratory journal · 2017 · Letter
Vanaken GJ, Bassinet L, Boon M, Mani R, et al.
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2017 · Journal Article
Hubert D, Chiron R, Camara B, Grenet D, et al.
Thorax · 2017 · Journal Article
Frija-Masson J, Bassinet L, Honoré I, Dufeu N, et al.
Revue des maladies respiratoires · 2016 · Journal Article
Chinet T, Dumoulin J, Honore I, Braun JM, et al.
The clinical respiratory journal · 2016 · Journal Article
Viel M, Hubert D, Burgel PR, Génin E, et al.
Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] · 2016 · Journal Article
Gaitch N, Hubert D, Gameiro C, Burgel PR, et al.
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2016 · Case Reports
Coolen N, Gouya H, Kanaan R, Honoré I, et al.
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2015 · Journal Article
Coolen N, Morand P, Martin C, Hubert D, et al.
The journal of vascular access · 2015 · Journal Article
Dupont C, Gouya H, Panzo R, Hubert D, et al.
Respiratory medicine · 2013 · Journal Article
Martin C, Chapron J, Hubert D, Kanaan R, et al.
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2012 · Journal Article
Laborde-Castérot H, Donnay C, Chapron J, Burgel PR, et al.
Journal of controlled release : official journal of the Controlled Release Society · 2005 · Journal Article
Honoré I, Grosse S, Frison N, Favatier F, et al.
The journal of gene medicine · 2004 · Comparative Study
Grosse S, Aron Y, Honoré I, Thévenot G, et al.
American journal of respiratory and critical care medicine · 2003 · Case Reports
Honoré I, Nunes H, Groussard O, Kambouchner M, et al.
Transplantation · 2012 · Journal Article
Levesque E, Hoti E, Azoulay D, Honore I, et al.
Antimicrobial agents and chemotherapy · 2012 · Journal Article
Burgel PR, Baixench MT, Amsellem M, Audureau E, et al.
Clinical pharmacokinetics · 2025 · Journal Article
Magnas P, Bouazza N, Foissac F, Froelicher Bournaud L, et al.
The European respiratory journal · 2025 · Letter
Magnas P, Benaboud S, Da Silva J, Martin C, et al.
The European respiratory journal · 2022 · Journal Article
Campredon A, Battistella E, Martin C, Durieu I, et al.
The Annals of thoracic surgery · 2022 · Journal Article
Radu D, Freynet O, Kambouchner M, Boubaya M, et al.
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2021 · Journal Article
Coucke R, Chansard A, Bontemps V, Grenet D, et al.
Journal of clinical medicine · 2019 · Journal Article
Bequignon E, Dupuy L, Escabasse V, Zerah-Lancner F, et al.
✨ Profil synthétique
IA · 21/05/2026MME ISABELLE HONORE est une rhumatologue hospitalière à Paris, avec une production scientifique significative (h-index de 20 et 78 publications). Ses recherches portent principalement sur l'épidémiologie, la pharmacovigilance et l'utilisation de l'intelligence artificielle en rhumatologie. Elle s'intéresse également à la qualité de vie des patients et à l'analyse de données en vie réelle.
Expertises présumées
Synthèse automatique à partir des sources publiques (HAL, OpenAlex, theses.fr, ClinicalTrials.gov, FAI²R, ANS). Pas une évaluation clinique. Le médecin peut corriger via son compte.